Table 1.
Baseline patient characteristics.
| Analysis population baseline characteristics | Arm 1 (N=56), n (%) | Arm 2 (N=33), n (%) | All (N=89), n (%) | |||
| Disease stage | ||||||
|
|
Metastatic | 39 (70) | 22 (67) | 61 (69) | ||
|
|
Nonmetastatic | 17 (30) | 11 (33) | 28 (32) | ||
| Disease type | ||||||
|
|
Renal cell carcinoma | 12 (21) | 9 (27) | 21 (24) | ||
|
|
Prostate adenocarcinoma | 44 (79) | 24 (73) | 68 (76) | ||
| Parent protocol type | ||||||
|
|
Unknown | 1 (2) | 2 (6) | 3 (3) | ||
|
|
Combination therapy | 10 (18) | 5 (15) | 15 (17) | ||
|
|
Hormone therapy | 35 (63) | 19 (58) | 54 (61) | ||
|
|
Targeted therapy | 10 (18) | 7 (21) | 17 (19) | ||
| Eastern Cooperative Oncology Group | ||||||
|
|
0 | 45 (80) | 25 (76) | 70 (79) | ||
|
|
1 | 10 (18) | 8 (24) | 18 (20) | ||
|
|
2 | 1 (2) | —a | 1 (1) | ||
| Internet use confidence scale | ||||||
|
|
Extremely confident | 38 (68) | 19 (58) | 57 (64) | ||
|
|
Somewhat confident | 18 (32) | 14 (42) | 32 (36) | ||
| Frequency of internet access | ||||||
|
|
1 time a week | 1 (2) | 1 (3) | 2 (2) | ||
|
|
2 times a week | 1 (2) | 1 (3) | 2 (2) | ||
|
|
5 or more times a week | 54 (96) | 31 (94) | 85 (96) | ||
| Number of times per week internet is accessed | ||||||
|
|
1 time a week | 1 (2) | 1 (3) | 2 (2) | ||
|
|
2 times a week | — | 1 (3) | 1 (1) | ||
|
|
3 times a week | — | 1 (3) | 1 (1) | ||
|
|
4 times a week | 1 (2) | — | 1 (1) | ||
|
|
5 or more times a week | 54 (96) | 30 (91) | 84 (94) | ||
|
|
All | 56 (100) | 33 (100) | 89 (100) | ||
| Baseline characteristics in patients who completed greater than or equal to 4 cycles | ||||||
| Parent protocol type | ||||||
| Unknown | 1 (2) | 1 (4) | 2 (3) | |||
| Combination therapy | 5 (12) | 1 (4) | 6 (9) | |||
| Hormone therapy | 34 (79) | 16 (70) | 50 (76) | |||
| Targeted therapy | 3 (7) | 5 (22) | 8 (12) | |||
| Disease stage | ||||||
| Metastatic | 26 (60) | 12 (52) | 38 (58) | |||
| Nonmetastatic | 17 (41) | 11 (48) | 28 (42) | |||
| All | 43 (100) | 23 (100) | 66 (100) | |||
aNot applicable.